About TeraImmune
TeraImmune is a company based in Gaithersburg (United States) founded in 2016 by Jihoon Park and Yongchan Kim was acquired by Baudax Bio in June 2023. TeraImmune operates in a competitive market with competitors including Poseida Therapeutics, Celgene, TScan Therapeutics, Sonoma Biotherapeutics and ArsenalBio, among others.
- Headquarter Gaithersburg, United States
- Founders Jihoon Park, Yongchan Kim
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$224.94 K (USD), Grant
Apr 01, 2018
-
Investors
HHS
& 1 more
-
Employee Count
Not available
-
Acquired by
Baudax Bio
(Jun 30, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of TeraImmune
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of TeraImmune
Investors in TeraImmune
TeraImmune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Baudax Bio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Develops innovative technologies for acute pain treatment in healthcare.
|
Locked | Locked | Locked |
Investor details for TeraImmune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TeraImmune
Investment portfolio details for TeraImmune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TeraImmune
Detailed financials for TeraImmune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Teraimmune Comparisons
Peer comparison for TeraImmune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TeraImmune
TeraImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Celgene, TScan Therapeutics, Sonoma Biotherapeutics and ArsenalBio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immune cell therapies
|
|
| Locked | Locked | Locked |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
Detailed competitors of TeraImmune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Teraimmune
Complete news archive for TeraImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TeraImmune
TeraImmune was founded in 2016 and raised its 1st funding round 2 years after it was founded.
TeraImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Yongchan Kim is the current CEO of TeraImmune. They have also founded this company.
TeraImmune was founded in 2016 and is based in Gaithersburg, United States, where operations focus on the biotechnology sector. T-cell therapies targeting hemophilia, multiple sclerosis, and B-cell lymphoma are advanced through a pipeline that includes TI-168, TI-235, and TI-385. Three patented technologies related to Treg cell production and receptors support these efforts in disease treatment.
TeraImmune's top competitors include Achilles Therapeutics, ArsenalBio and Poseida Therapeutics.
TeraImmune has 2 investors. Key investors include HHS, and Baudax Bio.